Fortress Biotech, Inc. (FBIO): Form 8-K filed 2026-11-13
- Accepted by EDGAR
- 2026-11-13 08:05 ET
- Event date
- 2026-11-13
- Accession no.
- 0001104659-26-126525
- Original filing
- SEC EDGAR filing index
AI summary of the filing text. It can contain mistakes; the original filing is authoritative.
Fortress Biotech reports third-quarter results and full repayment of Oaktree credit facility
Fortress Biotech reported third-quarter 2026 consolidated net revenue of $19.2 million, compared to $17.6 million in the third quarter of 2025. Net loss attributable to common stockholders was $(7.9) million, compared to net income of $3.7 million. The company also disclosed full repayment of its Oaktree credit facility in September 2026 and a subsidiary's licensing of FB-607.
- Net loss attributable to common stockholders was $(7.9) million, or $(0.23) per share basic and diluted.
- Consolidated cash and cash equivalents totaled $152.2 million as of September 30, 2026.
- Fortress repaid the remaining $15.0 million of Oaktree principal in September 2026 and has no outstanding debt at the parent level.
- A majority-owned subsidiary licensed FB-607 from Cedars-Sinai; it is in a Phase 2 study for irritable bowel syndrome with diarrhea.
earningsdebtmaterial agreement
Items reported
- Item 2.02: Results of Operations and Financial Condition
The company publicly announced results of operations or financial condition for a completed period, most often a quarterly earnings release. The release itself is usually attached as Exhibit 99.1. Information under Item 2.02 is generally "furnished" rather than "filed". - Item 9.01: Financial Statements and Exhibits
Lists the financial statements, pro forma information and exhibits filed with the report. It almost always accompanies another Item and is rarely news on its own.
Documents
| Type | Description | Document |
|---|---|---|
| 8-K | 8-K | fbio-20261113x8k.htm |
| EX-99.1 | EX-99.1 | fbio-ex99d1.htm |
The summary above was generated by AI from the filing text and checked automatically against it. Read the original documents on SEC EDGAR. How to read an 8-K.